While there is little role for antipsychotic monotherapy in OCD, SSRI-resistant OCD patients are likely to benefit from augmentation with atypical antipsychotics in around 50% of cases. Particular subgroups of OCD patients, notably those with comorbid tic disorder and those with schizotypal personality disorder, have been shown to respond more robustly to augmentation strategies in some trials of both typical and atypical antipsychotics (Keuneman et al., 2005).
Ref: - Keuneman, R.J., Pokos, V., Weerasundera, R. & Castle, D.J. (2005) Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Australian and New Zealand Journal of Psychiatry, 39, 5, 336-343.
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
| << < | Current | > >> | ||||
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
This blog on Clinical Psychopharmacology is maintained by Dr. Shahul Ameen, M.D., Psychiatrist, St. John's Hospital, Kattappana, Idukki, Kerala, India.
Psychopharmacology Tips is a part of PsyPlexus, a portal for mental health professionals.
This blog is only for educational purpose of psychiatrists and other physicians. The information published in this blog is not intended for use as a substitute for consultation to a licensed health professional. Patients and consumers who visit Psychopharmacology Tips should carefully review the information gathered from the site with a professional healthcare provider.